ArticleRwanda journal of medicine and health sciences2024
Assessment of Dyslipidaemia and Cardiovascular Disease Risk Factors among Type 2 Diabetes Mellitus Patients Attending Kabutare District Hospital, Huye, Rwanda.
Article in Rwanda journal of medicine and health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dyslipidaemia is a major contributing factor to the development of cardiovascular disease (CVD) in type 2 diabetic mellitus (T2DM) patients. People with T2DM are at a significantly high risk of developing dyslipidaemia which in turn is a risk factor for CVD. The objective of this study was to assess the risk factors for CVD in T2DM patients. Methodology: A descriptive cross-sectional study was conducted on 100 T2DM patients consecutively presenting at Kabutare District Hospital, Huye District southern Rwanda. Excluded were patients on lipid lowering drugs and those with chronic renal and liver diseases. Results: The overall prevalence of dyslipidaemia was 79% with hypoalphalipoproteinaemia (47%) being the most common and hypercholesterolaemia (29%) the least frequent. When stratified according to glycaemic control, median diastolic blood pressure was significantly higher (p=0.045) in participants whose median fasting plasma glucose (FPG) was ≥5.6 mmol/L. Median fasting triglycerides (p=0.006) and non-HDL-C (p=0.019) concentrations were significantly lower in euglycaemic participants compared to participants with median FPG ≥5.6 mmol/L. Dysglycaemia was significantly associated with dyslipidaemia status (p=0.001). Conclusion: Effective management and monitoring of dyslipidaemia, particularly among those with poor glycaemic control, is crucial in mitigating CVD risks in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.